GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Egetis Therapeutics AB (LTS:0ABW) » Definitions » Quick Ratio

Egetis Therapeutics AB (LTS:0ABW) Quick Ratio : 0.98 (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Egetis Therapeutics AB Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Egetis Therapeutics AB's quick ratio for the quarter that ended in Sep. 2024 was 0.98.

Egetis Therapeutics AB has a quick ratio of 0.98. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Egetis Therapeutics AB's Quick Ratio or its related term are showing as below:

LTS:0ABW' s Quick Ratio Range Over the Past 10 Years
Min: 0.98   Med: 7.7   Max: 65.88
Current: 0.98

During the past 13 years, Egetis Therapeutics AB's highest Quick Ratio was 65.88. The lowest was 0.98. And the median was 7.70.

LTS:0ABW's Quick Ratio is ranked worse than
79.51% of 1503 companies
in the Biotechnology industry
Industry Median: 3.41 vs LTS:0ABW: 0.98

Egetis Therapeutics AB Quick Ratio Historical Data

The historical data trend for Egetis Therapeutics AB's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egetis Therapeutics AB Quick Ratio Chart

Egetis Therapeutics AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.76 4.23 3.88 2.97 3.32

Egetis Therapeutics AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.93 3.32 2.53 1.55 0.98

Competitive Comparison of Egetis Therapeutics AB's Quick Ratio

For the Biotechnology subindustry, Egetis Therapeutics AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egetis Therapeutics AB's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Quick Ratio falls into.



Egetis Therapeutics AB Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Egetis Therapeutics AB's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(345.9-0.7)/103.9
=3.32

Egetis Therapeutics AB's Quick Ratio for the quarter that ended in Sep. 2024 is calculated as

Quick Ratio (Q: Sep. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(164.4-0.6)/167
=0.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Egetis Therapeutics AB  (LTS:0ABW) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Egetis Therapeutics AB Quick Ratio Related Terms

Thank you for viewing the detailed overview of Egetis Therapeutics AB's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Egetis Therapeutics AB Business Description

Traded in Other Exchanges
Address
Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.

Egetis Therapeutics AB Headlines

No Headlines